Stopping renin-angiotensin-aldosterone inhibitors after hyperkalemia may offset their potential clinical benefits, according to investigators.
Investigators report a low incidence of hypokalemia and hypomagnesemia after a single dose of patiromer monotherapy.
Potassium binders historically have been used short term or intermittently.
Discontinuation of RAAS inhibitors is often the first approach to manage hyperkalemia.
New findings have important implications in the new era where delaying dialysis initiation is a priority goal by means of continued conservative management of hyperkalemia, according to investigators.
Both potassium binders effectively lowered serum potassium levels in patients on hemodialysis meeting hyperkalemia definitions, compared with no treatment, investigators reported.
Patients with a high risk of hyperkalemia according to the nomogram need timely and continuous monitoring of serum potassium, the investigators stated.
Each of the 4 potassium binders that were compared in a study had advantages and disadvantages, investigators reported.
Patiromer was well tolerated in patients with nondialysis-dependent chronic kidney disease stages 1 to 5.
A committee of nephrologists and cardiologists developed 6 recommendations to improve hyperkalemia management.